| CAS NO: | 61-68-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1g | 询价 |
| 2g | 询价 |
| 5g | 询价 |
| 10g | 询价 |
| 25g | 询价 |
| 50g | 询价 |
| 100g | 询价 |
| Molecular Weight (MW) | 241.29 |
|---|---|
| Formula | C15H15NO2 |
| CAS No. | 61-68-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 48 mg/mL (198.9 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 2-(2,3-dimethylanilino)benzoic acid InChi Key: HYYBABOKPJLUIN-UHFFFAOYSA-N InChi Code: InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/ h3-9,16H,1-2H3,(H,17,18) SMILES: c1(c(cccc1)C(=O)O)Nc1c(c(ccc1)C)C |
| Synonyms | CI-473; CN-35355; CI473; CN35355; CI 473; CN 35355; Mefenamic Acid; Ponstel; Parkemed; Coslan |
| In Vitro | In vitro activity: Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of hCOX-1, with IC50s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively. Mefenamic acid (0-100 μM) has cytotoxic effects on KB, Saos-2, and 1321N cells, however, U-87MG cells are resistant to Mefenamic acid. Cell Assay: Powder forms of Mefenamic acid, indometacin, aspirin, and celecoxib are dissolved in 0.1% dimethyl sulfoxide (DMSO) to achieve a concentration of 100 μM of stock solution, which is sterilized by filtration through a 0.22-μm filter and then stored at 4°C. Different concentrations (100, 50, 25, 10, and 5 μM) of the drugs (Mefenamic acid, etc.) are prepared by serial dilutions with the FCS-free medium or the medium containing 10% FCS in sterile plastic centrifuge tubes |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | [1]. Gierse JK, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 (Pt 2):479-84. [2]. Hashemipour MA, et al. In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines. J Dent (Shiraz). 2016 Sep;17(3):219-25. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |
